A medical worker holds a dose of the Sinovac vaccine at a district health facility as Indonesia begins mass vaccination for the coronavirus disease (Covid-19), starting with its healthcare workers, in Jakarta, Indonesia. - Reuters
JAKARTA, May 15 (Bloomberg): Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months.
Over in Beijing, though, the company’s chief executive officer was unaware.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
